OpenClinica Launches Program Designed to Match OpenClinica’s Enterprise Technology with CRO Services
OpenClinica
is launching a program designed to match OpenClinica’s Enterprise technology with Contract Research Organization (CRO) services to deliver enhanced customer offerings.
Ben Baumann, OpenClinica’s director of business development, says this program will be appropriate for both domestic and international organizations.
“As the leader in using open source technology to improve clinical research, OpenClinica, is expanding its capabilities and reach by partnering with other forward thinking organizations who understand the substantial value that a professionally implemented and well developed open source solution can bring to clinical trial operations,” Baumann said.
OpenClinica is expanding the OpenClinica Partner Program to:
- Provide a framework for organizations offering value-added services around OpenClinica.
- Leverage the strengths of each party and bring these strengths to bear in customer solutions that are higher quality than they would be otherwise.
- Drive the success of our partners and increase the value received from selecting OpenClinica as their electronic data capture (EDC) and clinical data management platform (CDM).
OpenClinica is presently fielding inquiries from companies interested in learning more about the Partner Program. For more information go to:
https://www.openclinica.com/partner-inquiry
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
